Patents by Inventor Gina Finan

Gina Finan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of cognitive disorders using nitazoxanide (NTZ), nitazoxanide (NTZ) analogs, and metabolites thereof
    Patent number: 12239635
    Abstract: Compounds and pharmaceutical compositions effective for treating cognitive disorders are described. The compounds and pharmaceutical compositions described include Nitazoxanide (NTZ), Nitazoxanide (NTZ) analogs, Nitazoxanide (NTZ) metabolites, or Nitazoxanide (NTZ) metabolite analogs. Methods of treating, ameliorating, and/or preventing cognitive disorders using the compounds and pharmaceutical compositions disclosed herein are also described.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: March 4, 2025
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Tae-Wan Kim, Gina Finan
  • TREATMENT OF COGNITIVE DISORDERS USING NITAZOXANIDE (NTZ), NITAZOXANIDE (NTZ) ANALOGS, AND METABOLITES THEREOF
    Publication number: 20210137896
    Abstract: Compounds and pharmaceutical compositions effective for treating cognitive disorders are described. The compounds and pharmaceutical compositions described include Nitazoxanide (NTZ), Nitazoxanide (NTZ) analogs, Nitazoxanide (NTZ) metabolites, or Nitazoxanide (NTZ) metabolite analogs. Methods of treating, ameliorating, and/or preventing cognitive disorders using the compounds and pharmaceutical compositions disclosed herein are also described.
    Type: Application
    Filed: December 11, 2020
    Publication date: May 13, 2021
    Inventors: Tae-Wan KIM, Gina FINAN
  • Methods of reducing levels of tau
    Patent number: 9696306
    Abstract: Successful CNS drug discovery requires a scalable, highly physiological neuronal model. Using directed differentiation of mouse embryonic stem (mES) cells, including mES cells isolated from a mouse model of Alzheimer's disease (AD), a highly homogeneous primary neuronal model amenable to phenotypic assays for production and synaptotoxicity of amyloid ?-peptide was developed. This model furnishes a highly physiological and AD-relevant platform suitable for high throughput small molecule and functional genetic screens, providing specific small molecule compounds identified by such screens.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: July 4, 2017
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Tae-Wan Kim, Laura Beth Johnson McIntire, Natalie Landman, Gina Finan
  • Screening Assays Using Stem Cells and Stem Cell-Derived Neurons from Mouse Models of Alzheimer's Disease
    Publication number: 20140171380
    Abstract: Successful CNS drug discovery requires a scalable, highly physiological neuronal model. Using directed differentiation of mouse embryonic stem (mES) cells, including mES cells isolated from a mouse model of Alzheimer's disease (AD), a highly homogeneous primary neuronal model amenable to phenotypic assays for production and synaptotoxicity of amyloid ?-peptide was developed. This model furnishes a highly physiological and AD-relevant platform suitable for high throughput small molecule and functional genetic screens, providing specific small molecule compounds identified by such screens.
    Type: Application
    Filed: September 6, 2013
    Publication date: June 19, 2014
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Tae-Wan Kim, Laura Beth Johnson McIntire, Natalie Landman, Gina Finan